Biontech

Biontech EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Biontech (BNTX) as of Sep 21, 2026 is 15.01. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -8.39 — a change of -278.85% (higher).

EV/FCF

15.01

YoY

-278.85%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Biontech is 2026 15.01 . EV/FCF (Enterprise Value to Free Cash Flow) of Biontech was 2025 -8.39 . It decreases by -278.85% higher compared to the previous year.

The Biontech EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-144.53 EUR
Jan 1, 2019
-67.35 EUR
Jan 1, 2020
-176.68 EUR
Jan 1, 2021
22.84 EUR
Jan 1, 2022
0.36 EUR
Jan 1, 2023
0.48 EUR
Jan 1, 2024
-8.39 EUR
Jan 1, 2025
15.01 EUR
The Biontech EV/FCF history
YEAREV/FCFYoY
15.01-278.85%
-8.39-1,834.97%
0.48+34.97%
0.36-98.43%
22.84-112.93%
-176.68+162.34%
-67.35-53.40%
-144.53-13.57%
-167.22
Access this data via the Eulerpool API

Biontech Stock analysis

What does Biontech do? BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biontech stock

EV/FCF (Enterprise Value to Free Cash Flow) of Biontech is 15.01 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Biontech changed from -8.39 to 15.01, representing a -278.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Biontech since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Biontech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Biontech

All Key Metrics — Biontech